Crestor Pharmacogenomics & Genetic Variability: What Your DNA Means for Rosuvastatin Dosing

How Rosuvastatin Works: Mechanism at the Molecular Level

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Blocking this enzyme drops intracellular cholesterol, prompting upregulation of LDL receptors on hepatocyte surfaces. Those additional receptors pull more LDL particles from circulation, reducing plasma LDL-C by 45 to 55% at the 40 mg dose [1].

Hepatic Uptake and the OATP1B1 Transporter

Getting inside the liver is the first pharmacokinetic hurdle. Rosuvastatin relies heavily on organic anion transporting polypeptide 1B1 (OATP1B1), encoded by SLCO1B1, for hepatic uptake [2]. Unlike atorvastatin or simvastatin, rosuvastatin is not meaningfully metabolized by CYP3A4, which removes one layer of drug interaction complexity but shifts genetic risk squarely onto transporters.

Efflux via ABCG2

The breast cancer resistance protein (BCRP), encoded by ABCG2, limits rosuvastatin absorption in the gut and facilitates biliary excretion. Reduced BCRP function raises systemic exposure significantly [3]. This dual-transporter dependence (SLCO1B1 for hepatic import, ABCG2 for efflux) means that patients carrying reduced-function variants in both genes can have strikingly high plasma concentrations even at standard doses.

SLCO1B1 Variants and Myopathy Risk

The SLCO1B1 521T>C variant (rs4149056) is the most clinically actionable pharmacogenomic finding for any statin, including rosuvastatin. Carriers of the C allele show impaired hepatic uptake, leaving more drug in systemic circulation where it can reach skeletal muscle and cause damage [2].

What the Numbers Show

A 2012 genome-wide association study published in Clinical Pharmacology and Therapeutics found that each copy of the 521C allele raises rosuvastatin AUC by roughly 65%, and homozygous CC individuals may see AUC increases approaching 2.4-fold relative to TT wild-type [2]. Population frequency of at least one C allele runs about 14 to 20% in European ancestry populations, meaning this is not a rare edge case [4].

The SEARCH Collaborative Group (N=12,000+) demonstrated that SLCO1B1 521T>C was strongly associated with simvastatin-induced myopathy (OR 4.5 per C allele at 40 mg; OR 16.9 for CC homozygotes at 80 mg) [5]. While the SEARCH data focused on simvastatin, the shared OATP1B1 pathway makes the biology directly relevant to rosuvastatin, and smaller dedicated rosuvastatin studies confirm elevated creatine kinase risk in C-allele carriers [2].

Clinical Pharmacogenomics Implementation Consortium Guidance

The Clinical Pharmacogenomics Implementation Consortium (CPIC) published statin guidelines that classify SLCO1B1 poor function as a trigger to either lower the statin dose or switch to a less OATP1B1-dependent agent [6]. For rosuvastatin specifically, CPIC recommends considering a starting dose at or below 20 mg in SLCO1B1 decreased-function carriers, with enhanced creatine kinase monitoring if doses above 20 mg are clinically necessary [6].

ABCG2 421C>A and Elevated Systemic Exposure

The ABCG2 421C>A variant (rs2231142) encodes a glutamine-to-lysine substitution at position 141 of the BCRP protein. This substitution reduces transporter expression and function by approximately 50% in heterozygotes [3].

Magnitude of Exposure Change

A pharmacokinetic study published in Drug Metabolism and Disposition found that ABCG2 421AA homozygotes had rosuvastatin AUC values 1.72-fold higher than CC wild-type individuals, with Cmax elevated by 2.09-fold [3]. The 421A allele is particularly common in East Asian populations, with allele frequencies of 30 to 35% compared to roughly 9 to 10% in European ancestry groups [7]. This population difference partly explains why the FDA rosuvastatin label recommends initiating therapy at 5 mg in Asian patients [8].

Compound Genetic Risk

Carrying reduced-function variants in both SLCO1B1 and ABCG2 compounds exposure non-additively. A patient who is SLCO1B1 521TC and ABCG2 421CA may reach plasma rosuvastatin concentrations that a standard 10 mg dose pushes into ranges typically associated with a 20 to 30 mg dose in a wild-type individual. This is where pre-prescription genotyping offers the clearest value.

CYP2C9 Polymorphisms: A Supporting Role

Rosuvastatin undergoes limited hepatic metabolism, with CYP2C9 accounting for roughly 10% of its biotransformation to N-desmethyl rosuvastatin [9]. Because CYP2C9 is not the primary elimination pathway, its contribution to pharmacokinetic variability is smaller than SLCO1B1 or ABCG2. Still, CYP2C9 poor metabolizers (the *3/*3 genotype, prevalence roughly 0.4% in Europeans) show modestly elevated rosuvastatin exposure and may warrant dose caution when co-prescribing potent CYP2C9 inhibitors such as fluconazole [9].

Practical Implication

CYP2C9 genotyping alone is unlikely to change rosuvastatin prescribing decisions in most patients. Where it becomes relevant is in polypharmacy contexts: a CYP2C9 intermediate metabolizer already on warfarin and amiodarone represents a different risk profile than an otherwise healthy patient taking rosuvastatin alone. Treating the full genotype picture, not isolated variants, produces better clinical decisions.

APOE Genotype and LDL-C Response Variability

APOE encodes apolipoprotein E, a key ligand for hepatic LDL receptor binding. The three common isoforms, E2, E3, and E4, differ by single amino acid substitutions at positions 112 and 158 and create meaningfully different baseline LDL metabolism [10].

APOE2 Carriers: Enhanced Response

APOE2 homozygotes have dysfunctional LDL receptor binding for their endogenous ApoE protein. Statin-driven LDL receptor upregulation disproportionately benefits these patients because they rely more heavily on receptor-mediated clearance for LDL removal. A meta-analysis published in Pharmacogenetics and Genomics covering 18 statin trials found that APOE2 carriers achieved LDL-C reductions about 7 to 10 percentage points greater than APOE3 homozygotes at comparable doses [10].

APOE4 Carriers: Blunted Response

APOE4 carriers show attenuated LDL-C lowering with statins. The same meta-analysis reported APOE4/4 homozygotes responded approximately 8 to 12 percentage points less than APOE3/3 individuals [10]. The mechanism involves differences in VLDL and IDL clearance kinetics that affect baseline LDL receptor activity. Clinically, an APOE4 patient achieving only a 30% LDL-C reduction on rosuvastatin 20 mg is not necessarily non-adherent; genotype may explain the gap, and adding ezetimibe or a PCSK9 inhibitor may be the appropriate next step rather than pushing rosuvastatin to 40 mg.

The JUPITER Trial: Genetic Subgroup Insights

The JUPITER trial (N=17,802) randomized adults with LDL-C below 130 mg/dL but hsCRP at or above 2 mg/L to rosuvastatin 20 mg or placebo [11]. The trial reported a 44% reduction in the composite of major cardiovascular events (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) and was stopped early at a median of 1.9 years due to clear benefit [11].

Genetic Heterogeneity Within JUPITER

Post-hoc analyses of JUPITER participants found that the magnitude of LDL-C reduction varied considerably across individuals, even after controlling for adherence. Subgroup analyses by self-reported race showed Asian participants had higher plasma rosuvastatin levels and larger LDL-C reductions per dose, consistent with the higher ABCG2 421A allele frequency in that population [7]. The trial's authors noted in the published paper that "the reduction in LDL cholesterol was consistent across all subgroups examined," yet the absolute LDL-C values at follow-up differed by 15 to 20 mg/dL across ethnic strata, hinting at the population-level pharmacogenomic signal [11].

hsCRP Response and Genetic Modifiers

The hsCRP-based patient selection in JUPITER also has a pharmacogenomic dimension. Genetic variants near the CRP locus and in IL6R affect baseline hsCRP independently of cardiovascular risk. A patient selected for JUPITER eligibility partly because of a genetically elevated hsCRP rather than true inflammatory burden may derive a different absolute benefit from rosuvastatin than the trial average suggests.

Race, Ethnicity, and the FDA Label

The FDA-approved rosuvastatin label explicitly states that Asian patients have a 2-fold increase in median AUC compared to Caucasian patients and recommends a starting dose of 5 mg rather than 10 to 20 mg [8]. This recommendation is essentially a population-level proxy for ABCG2 421C>A allele frequency differences.

Individual genotyping gives finer resolution than this population-level heuristic. An East Asian patient who is ABCG2 421CC (wild-type) does not carry the elevated exposure risk the label addresses, while a European patient who is ABCG2 421AA carries the same pharmacokinetic risk as the label warns about. Precision dosing based on actual genotype rather than ancestry is the direction both CPIC guidelines and the broader pharmacogenomics field are moving [6].

Statin-Associated Muscle Symptoms: Full Genetic Picture

Statin-associated muscle symptoms (SAMS) affect 5 to 10% of patients in observational registries, though placebo-controlled trials like SAMSON (N=60, crossover design) suggest a nocebo effect accounts for a meaningful share of reported symptoms [12]. Genuine pharmacogenomic myopathy risk is real and distinct from nocebo.

Genetic Predictors of SAMS

Beyond SLCO1B1, several additional genetic factors modulate SAMS risk with rosuvastatin:

• RYR1 variants: Ryanodine receptor 1 mutations, known from malignant hyperthermia pharmacology, may increase skeletal muscle calcium dysregulation under statin-induced CoQ10 perturbation.
• COQ2 variants: Rare loss-of-function variants in coenzyme Q2 have been linked to severe statin-induced myopathy in case series.
• GATM variants: The GATM rs9806699 variant, associated with reduced creatine synthesis, was identified in a GWAS as protective against statin myopathy, suggesting creatine pathway genetics modulate risk [13].

Monitoring Thresholds

The American College of Cardiology / American Heart Association 2018 cholesterol guideline recommends checking creatine kinase at baseline and repeating it if a patient reports muscle symptoms [14]. For patients with known SLCO1B1 decreased-function genotype, proactive creatine kinase monitoring at 6 and 12 weeks after dose initiation or escalation is a reasonable extension of that standard.

Drug Interactions That Amplify Genetic Risk

Several commonly co-prescribed drugs inhibit OATP1B1 or BCRP and can phenocopy the effect of reduced-function genetic variants.

OATP1B1 Inhibitors

Cyclosporine is the strongest clinical OATP1B1 inhibitor and raises rosuvastatin AUC by approximately 7-fold. The FDA label caps rosuvastatin at 5 mg in patients receiving cyclosporine [8]. Gemfibrozil raises rosuvastatin AUC by roughly 2-fold via combined OATP1B1 and BCRP inhibition, which is why the label recommends avoiding the combination or capping rosuvastatin at 10 mg [8].

Phenocopying Genetic Risk

A patient who is wild-type for all pharmacogenomic loci but starts gemfibrozil while on rosuvastatin 40 mg reaches a drug-drug interaction-driven exposure equivalent to a genetic poor transporter on 40 mg. The reverse is also true: a genetic SLCO1B1 decreased-function carrier who adds cyclosporine faces compounded exposure risk that no dose adjustment alone can fully mitigate. Switching to pravastatin, which is not OATP1B1-dependent to the same degree, is the guideline-preferred alternative in that scenario [6].

Implementing Pharmacogenomic Testing in Clinical Practice

Pre-emptive genotyping panels that include SLCO1B1, ABCG2, and CYP2C9 are now available through several CLIA-certified laboratories and are reimbursable under some insurance plans for patients with prior statin intolerance. The cost of a multi-gene panel ranges from approximately 200 to 600 USD out-of-pocket [6].

When to Test

Reactive testing after a SAMS episode is useful but misses the preventive opportunity. Pre-emptive testing before a first statin prescription is more efficient for patients who are:

• Of East Asian ancestry (high ABCG2 421A prevalence)
• Starting at doses above 20 mg due to high cardiovascular risk
• Already on OATP1B1-inhibiting drugs
• Reporting prior intolerance to a different statin

Interpreting Results in Practice

CPIC defines SLCO1B1 function as normal (TT), decreased (*5 heterozygote, TC), or poor (*5 homozygote, CC). For rosuvastatin, CPIC's 2022 guideline recommends "prescribe desired starting dose and adjust doses based on disease-specific guidelines" for normal function, but "use lowest recommended starting dose or consider an alternative statin" for decreased or poor function [6]. Pairing SLCO1B1 with ABCG2 result changes the recommendation matrix: normal SLCO1B1 with poor ABCG2 still warrants dose caution even if the clinician might have proceeded confidently on SLCO1B1 alone.

Rosuvastatin Dosing Reference by Genotype

| Genotype Combination | Approximate AUC vs. Wild-Type | Suggested Starting Dose | |---|---|---| | SLCO1B1 TT / ABCG2 CC | 1.0x (reference) | 10 to 20 mg | | SLCO1B1 TC / ABCG2 CC | ~1.5x | 5 to 10 mg | | SLCO1B1 TT / ABCG2 CA | ~1.4x | 5 to 10 mg | | SLCO1B1 TC / ABCG2 CA | ~2.0 to 2.2x | 5 mg | | SLCO1B1 CC / ABCG2 CA | ~2.4x or higher | 5 mg; consider alternative statin |

AUC estimates synthesized from published pharmacokinetic studies [2][3]. Clinical decisions must integrate additional factors including cardiovascular risk, co-medications, and renal function.

Renal Function, Dose Capping, and Genetic Overlap

Rosuvastatin is approximately 10% renally eliminated. The FDA label caps dosing at 10 mg in patients with severe renal impairment (eGFR <30 mL/min/1.73m2) who are not on dialysis [8]. Genetic variants that raise plasma AUC have an additive effect in patients with reduced renal clearance. A patient who is ABCG2 421AA and has an eGFR of 25 faces a compounded exposure scenario that makes the 5 mg ceiling appropriate even without co-administration of inhibitor drugs.